汇宇制药(688553) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 1,093.20 million, an increase of 17.92% compared to the previous year[3] - Operating profit surged to RMB 354.91 million, reflecting a growth of 185.37% year-over-year[3] - Net profit attributable to shareholders was RMB 330.89 million, up 136.71% from the prior year[3] - The net profit excluding non-recurring gains was RMB 100.63 million, representing a 52.44% increase year-over-year[3] - Basic earnings per share increased to RMB 0.78, a rise of 137.6% compared to the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 5,208.53 million, an 11.16% increase from the beginning of the period[3] - Shareholders' equity attributable to the parent company was RMB 3,978.76 million, up 5.41% from the start of the period[3] Market Growth - The company experienced significant growth in international markets, with revenue from international operations increasing by RMB 77.50 million[6] Investment Gains - The fair value change gain from the investment in Zhejiang Tongyuan Kang Pharmaceutical Co., Ltd. was RMB 211 million during the reporting period[6] Financial Reporting Assurance - The company does not foresee any major uncertainties affecting the accuracy of the financial report[9]